Overview

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of the tumor. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining interferon alfa with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa with thalidomide in treating patients who have stage IV melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Southwest Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Interferon-alpha
Interferons
Thalidomide